title: Danaparoid for cardiopulmonary bypass in patients with previous heparin-induced thrombocytopenia.
abstract: Anticoagulation for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia requires the use of other anticoagulants. We report a case in whom this was achieved using the heparinoid danaparoid (Orgaran). Based on our experience and a review of the literature, we provide guidelines for managing these rare patients. A danaparoid dose substantially lower than that recommended by the manufacturer may minimize bleeding complications.
authors.affiliation: Department of Haematology, Hadassah University Medical Centre, Ein Karem, Jerusalem, Israel.
authors.forename: S
authors.initials: S
authors.lastname: Gillis
authors.forename: G
authors.initials: G
authors.lastname: Merin
authors.forename: D
authors.initials: D
authors.lastname: Zahger
authors.forename: M
authors.initials: M
authors.lastname: Deeb
authors.forename: B
authors.initials: B
authors.lastname: Drenger
authors.forename: E
authors.initials: E
authors.lastname: Hyam
authors.forename: A
authors.initials: A
authors.lastname: Eldor
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects*; D002315:Cardiopulmonary Bypass; D002809:Chondroitin Sulfates / Q000627:therapeutic use*; D003871:Dermatan Sulfate / Q000627:therapeutic use*; D004338:Drug Combinations; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects*; D006497:Heparan Sulfate / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013921:Thrombocytopenia / Q000139:chemically induced*
chemical_list: D000925:Anticoagulants; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004338:Drug Combinations; D006495:Heparin, Low-Molecular-Weight; D006497:Heparan Sulfate; C035838:danaparoid